“Cancer preoccupies us, and child cancer occupies us.”

Our work

We are working on the development of the drug CEB-01 with the objective of meeting unmet medical needs in oncology, and ensure surgeons and patients that the surgical site is free from cancerous cells.


At Cebiotex we have created a new medical product through our proprietary technology in nanofiber engineering, alongside the medical and scientific teams of the Sant Joan de Déu Barcelona Children’s Hospital (HSJD) and the Polytechnic University of Catalonia (UPC).


After finalising the Preclinical Phase with extremely promising results, we have initiated the Clinical Phase 2a. We are currently studying the security of CEB-01 in the indication of Soft Tissue Sarcomas (STS) with adult patients at Hospital de la Santa Creu i Sant Pau in Barcelona.

Latest discoveries

Latest News

Cebiotex at the American Society of Clinical Oncology 2021

ASCO21: First-in-human administration of CEB-01, a novel drug delivery implant matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) after surgery: Preliminary safety and pharmacokinetics report. …

Cebiotex highlighted in Biocat’s new report

Cover of the BioRegió de Catalunya report. Source: Biocat and CataloniaBio & HealthTech. Cebiotex has been highlighted in the recent ‘BioRegió de Catalunya 2020’ report among the nine Biotech and …